320 related articles for article (PubMed ID: 17018618)
41. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
42. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
Bajgelman MC; Strauss BE
Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917
[TBL] [Abstract][Full Text] [Related]
43. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
44. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
Inoue T; Leman ES; Yeater DB; Getzenberg RH
Prostate; 2008 Jul; 68(10):1048-56. PubMed ID: 18386260
[TBL] [Abstract][Full Text] [Related]
45. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
46. Gamma tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR gamma-dependent mechanism in PC-3 human prostate cancer cells.
Campbell SE; Musich PR; Whaley SG; Stimmel JB; Leesnitzer LM; Dessus-Babus S; Duffourc M; Stone W; Newman RA; Yang P; Krishnan K
Nutr Cancer; 2009; 61(5):649-62. PubMed ID: 19838939
[TBL] [Abstract][Full Text] [Related]
47. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth.
Nie D; Hillman GG; Geddes T; Tang K; Pierson C; Grignon DJ; Honn KV
Cancer Res; 1998 Sep; 58(18):4047-51. PubMed ID: 9751607
[TBL] [Abstract][Full Text] [Related]
48. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
49. Human 15-lipoxygenase: induction by interleukin-4 and insights into positional specificity.
Sigal E; Sloane DL; Conrad DJ
J Lipid Mediat; 1993; 6(1-3):75-88. PubMed ID: 8358018
[TBL] [Abstract][Full Text] [Related]
50. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
51. Detection and subcellular localization of two 15S-lipoxygenases in human cornea.
Chang MS; Schneider C; Roberts RL; Shappell SB; Haselton FR; Boeglin WE; Brash AR
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):849-56. PubMed ID: 15728540
[TBL] [Abstract][Full Text] [Related]
52. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.
Choi MS; Oh JH; Kim SM; Jung HY; Yoo HS; Lee YM; Moon DC; Han SB; Hong JT
Int J Oncol; 2009 May; 34(5):1221-30. PubMed ID: 19360335
[TBL] [Abstract][Full Text] [Related]
53. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
54. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase.
Moretti RM; Montagnani Marelli M; Sala A; Motta M; Limonta P
Int J Cancer; 2004 Oct; 112(1):87-93. PubMed ID: 15305379
[TBL] [Abstract][Full Text] [Related]
55. Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.
Bera A; Leighton XM; Pollard H; Srivastava M
Trends Cancer Res; 2018; 13():55-62. PubMed ID: 30369774
[TBL] [Abstract][Full Text] [Related]
56. Expression of 5-lipoxygenase (5-LOX) in T lymphocytes.
Cook-Moreau JM; El-Makhour Hojeij Y; Barrière G; Rabinovitch-Chable HC; Faucher KS; Sturtz FG; Rigaud MA
Immunology; 2007 Oct; 122(2):157-66. PubMed ID: 17484769
[TBL] [Abstract][Full Text] [Related]
57. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
58. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
Kelavkar UP; Cohen C; Kamitani H; Eling TE; Badr KF
Carcinogenesis; 2000 Oct; 21(10):1777-87. PubMed ID: 11023533
[TBL] [Abstract][Full Text] [Related]
59. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
60. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration.
Liu JW; Shen JJ; Tanzillo-Swarts A; Bhatia B; Maldonado CM; Person MD; Lau SS; Tang DG
Oncogene; 2003 Mar; 22(10):1475-85. PubMed ID: 12629510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
